3 Stocks Worth Watching for Action: Skye Bioscience (SKYE), Cardiol Therapeutics (CRDL), Atara Biotherapeutics (ATRA)

The biotech and healthcare industries remain highly active as investors focus on companies developing next-generation treatments and expanding their market presence. With clinical milestones, regulatory developments, and trading activity shaping sentiment, smaller-cap healthcare firms continue to present both opportunity and risk for market participants.

Skye Bioscience Inc (SKYE)

Skye Bioscience Inc (NASDAQ: SKYE) established an initial surge of 6.04% at $0.77, as the Stock market unbolted on May 20, 2026. During the day, the stock rose to $0.77 and sank to $0.73. Taking a more long-term approach, SKYE posted a 52-week range of $0.57-$5.75.

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 28.34%. Meanwhile, its Annual Earnings per share during the time was 28.34%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 31.03%. This publicly-traded company’s shares outstanding now amount to $35.13 million, simultaneously with a float of $22.96 million. The organization now has a market capitalization of $27.03 million.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is continuing to broaden its cardiovascular pipeline by targeting inflammatory conditions that currently lack effective disease-specific therapies. As the role of inflammation in cardiac disease becomes increasingly recognized, companies developing therapies focused on underlying disease mechanisms are drawing growing attention from investors and clinicians alike.

Market Momentum

As of May 20, 2026, CRDL closed at $1.30, up 3.17%, with trading volume of 253,604 shares versus an average volume of 678,983 shares. The company currently carries a market capitalization of $149.854M and a beta of 0.43, reflecting relatively controlled volatility compared to many clinical-stage biotech peers. Shares continue trading within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.34 indicates meaningful upside potential tied to future clinical advancement.

Clinical Expansion: Acute Myocarditis

Cardiol’s Phase II ARCHER study evaluated CardiolRx™ in acute myocarditis, an inflammatory condition affecting the heart muscle that can lead to arrhythmias, impaired cardiac function, and heart failure. Clinical findings demonstrated reductions in cardiac inflammation along with structural improvements, including decreases in left ventricular mass, an important indicator associated with cardiac remodeling and recovery.

Addressing Unmet Need

Current treatment approaches for myocarditis remain largely supportive, with limited therapies directly targeting inflammatory disease progression. Cardiol’s strategy of addressing the inflammatory drivers of cardiac injury may provide a differentiated therapeutic approach for patients who currently face few targeted treatment alternatives.

Outlook

As Cardiol continues building clinical evidence across multiple inflammatory cardiovascular conditions, successful advancement in myocarditis could significantly expand the company’s long-term commercial opportunity while strengthening the broader value of its development platform.

Atara Biotherapeutics Inc (ATRA)

Witnessing the stock’s movement on the chart, on May 20, 2026, Atara Biotherapeutics Inc (NASDAQ: ATRA) set off with pace as it heaved 0.43% to $9.45. During the day, the stock rose to $9.63 and sank to $9.00. Taking a more long-term approach, ATRA posted a 52-week range of $3.92-$19.15.

Nevertheless, the stock’s Earnings Per Share (EPS) this year is -130.96%. This publicly-traded company’s shares outstanding now amount to $8.51 million, simultaneously with a float of $5.83 million. The organization now has a market capitalization of $85.15 million. Its Quick Ratio in the last reported quarter now stands at 2.16. Another valuable indicator worth pondering is a publicly-traded company’s price-to-sales ratio for the trailing twelve months, which is currently 3.68.